Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix in Deal with MWG Biotech of Germany

Premium

Affymetrix of Santa Clara, Calif., said it has signed a licensing agreement with MWG-Biotech of Ebersberg, Germany, granting the German company the rights to certain Affymetrix intellectual property for commercializing low and medium density DNA arrays.

 

Under the terms of the license, MWG-Biotech has a non-exclusive, worldwide, royalty-bearing license that allows them to manufacture, use and sell low and medium density pre-spotted arrays.

 

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.